Clozapine Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25mg, 50mg, 100mg
Reference Brands: Clozaril (USA/EU), Sizopin (India)
Category:
Antipsychotropic Drugs
Clozapine is used to treat severely ill patients with schizophrenia who have used other medicines that did not work well. It is also used to lower risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder.
Clozapine Tablet is available in Tablets
and strengths such as 25mg, 50mg, 100mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Clozapine Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Clozapine Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Clozapine is an atypical antipsychotic medication primarily used in the management of treatment-resistant schizophrenia. It is generally reserved for patients who do not respond adequately to other antipsychotic therapies due to its potential for serious adverse effects and the need for regular monitoring. Clozapine works by modulating neurotransmitters in the brain, particularly dopamine and serotonin, helping to improve symptoms such as hallucinations, delusions, and disorganized thinking.
Despite not being a first-line treatment, clozapine offers significant clinical advantages. It has been shown to reduce the risk of suicidal behavior in patients with schizophrenia and schizoaffective disorder, including those who are not strictly treatment-resistant. Additionally, it is associated with a lower risk of tardive dyskinesia and may lead to fewer relapses compared to other antipsychotics. With appropriate monitoring and careful patient selection, clozapine remains a highly effective option for improving long-term outcomes in complex psychiatric cases.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing